Neuronetics, Inc. Common Stock (STIM) — Analysis Summary
Neuronetics, Inc. Common Stock (STIM) has a market cap of $124.56M with year-over-year revenue growth of +99.2%. Net margin stands at -26.1%. The stock trades at a P/E ratio of -3.4.
Key Takeaways
- Revenue changed +99.2% year-over-year
- Net margin of -26.1%
- P/E ratio of -3.4
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, STIM posted revenue growth of +99.2% and trades at a P/E of -3.4.
Neuronetics, Inc. Common Stock (STIM)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -3.4x — earnings do not cover interest payments
D/E at 3.6x — high financial leverage
Operating margin at -19.4% — material operating losses
Net margin at -24.5% — significant losses
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
658
Headquarters
MALVERN, PA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.